SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalculus Vct Regulatory News (CLC)

Share Price Information for Calculus Vct (CLC)

Share Price is delayed by 15 minutes
Get Live Data
53.25    0.00 (0.00%)
Bid:
48.00
Ask:
58.50
Spread: 10.50 (21.875%)
Market Cap: £51.93m
CLC Live PriceLast checked at - London Stock Exchange

Intraday Calculus Vct Share Chart

Interim Management Statement

17 Jan 2011 14:58

Investec Structured Products Calculus VCT plc

Interim Management Statement

17 January 2011

Investec Structured Products Calculus VCT plc ("the Company") announces its Interim Management Statement for the period from 1 September 2010 to 30 November 2010. This Statement also includes relevant financial information between the end of the period to the date of this Statement.

The Company is a tax efficient listed company which aims to achieve a regular tax free dividend stream together with capital growth for private investors. The Company brings together Investec Structured Product's award winning expertise in structured products and Calculus Capital's award winning expertise in venture capital.

Investec Structured Products Calculus VCT plc was launched in March 2010, and has raised £4.79 million to date (before expenses).

Headlines

- The unaudited net asset value ("NAV") per Ordinary Share as at 30 November2010 was 97.98 pence (including current period revenue) compared to 94.55pence at 31 August 2010 and 95.00 pence immediately following the close of theinitial fundraising on 30 April 2010.

- The Company launched a top up offer of Ordinary Shares in September 2010, raising £0.92 million (before expenses) before closing in December 2010.

- The Company made a second qualifying venture capital investment during theperiod, investing £299,377 in Lime Technology, a leading provider of renewablebuilding materials to the construction industry.

Since 30 November 2010 the unaudited NAV (including current period revenue) has risen to 101.23 pence as at 31 December 2010.

Investment in Structured Products

As at 30 November 2010, the following investments had been made instructured products. The structured products will achieve their target returnsubject to the Final Index Level of the FTSE 100 being higher than the InitialIndex Level*. The capital is at risk on a one for one basis ("CAR") if theFTSE 100 Index falls more than 50% at any time during the investment term andfails to fully recover at maturity such that the Final Index Level is belowthe Initial Index Level. FTSE 100 Return/ % of Initial Capital Investable Index at Risk Application

Issuer Strike Date Level No. of Units Unit Purchase Price Maturity Date (CAR) Money The Royal Bank 05/05/2010 5342 275,000 £0.96

12/05/2015 162.5% if 6.40%of Scotland FTSE 100plc higher*; CAR if FTSE 100 falls by more than 50%Investec Bank 14/05/2010 5263 500,000 £0.9791 19/11/2015 185% if 11.87%plc FTSE 100 higher*; CAR if FTSE 100 falls by more than 50%Santander 25/05/2010 4941 350,000 £0.9898 18/11/2015 185% if 8.40%Global Banking FTSE 100and Markets higher*;(Abbey CAR ifNational FTSE 100Treasury falls byServices plc) more than 50%Nomura Bank 28/05/2010 5188 350,000 £0.98 20/02/2013 137% if 8.32%International FTSE 100plc higher*; CAR if FTSE 100 falls by more than 50%

Morgan Stanley 10/06/2010 5133 500,000 £1.00 17/12/2012 134% if 12.13% FTSE 100 higher*; CAR if FTSE 100 falls by more than 50%HSBC Bank plc 01/07/2010 4806 500,000 £1.00

06/07/2012 125.1% if 12.13% FTSE 100 higher*; CAR if FTSE 100 falls by more than 50%

\* The Final Index Level is calculated using `averaging', meaning that the average of the closing levels of the FTSE 100 is taken on each Business Day over the last 2 - 6 months of the structured product plan term (the length of the averaging period differs for each plan).

The use of averaging to calculate the return can reduce adverse effects of a falling market or sudden market falls shortly before maturity. Equally, it can reduce the benefits of an increasing market or sudden market rises shortly before maturity.

The total amount invested in structured products as at 30 November 2010 was £2,442,980, representing 59.25 per cent. of net funds raised.

Qualifying Venture Capital Investment

In November 2010, £299,377 was invested in Lime Technology Limited("Lime"). The investment comprised £49,377 in B shares and £250,000 in 7 percent. long term loan stock, the investment in B ordinary shares representing0.47 per cent. of the share capital of Lime. The total funding round in Limewas £2.58 million, with £1.28 million also being invested by Calculus CapitalEIS Funds.Lime, which was established in 2002, produces renewable low carbonbuilding materials for the construction industry. The company's lead product,Tradical® Hemcrete®, is a negative carbon bio-composite product comprised ofhemp and lime based binder. Through its subsidiary, Hemp Technology, Limecontrols the hemp supply chain from seed to finished wall.

The total amount invested in qualifying venture capital investments as at 30 November 2010 was £549,377 representing 13.32 per cent of net funds raised.

C Share OfferIn September 2010, shareholders approved resolutions enabling theCompany to establish and raise money for a separate fund through the issue ofC ordinary shares of 1 pence each in the capital of the Company ("C Shares").The C Share offer to raise £25 million was launched on 7 January 2011 ("CShare Offer").The C Shares fund will be managed separately from the OrdinaryShares fund, with an investment remit similar to that of the Ordinary Sharesfund, but will include the ability to invest in structured products linked tothe performance of certain global equity indices in addition to the FTSE 100.The target return profile for the C Shares fund will be an annualtarget dividend of 4.5 pence per C Share for the first five years, an interimreturn of 47.5 pence per C Share by 14 March 2017 (which would (including thepayment of annual dividends) return the net 70.0 pence investment) with afurther 45.0 pence per C Share being returned by 14 March 2019 (which wouldachieve a total return of 115 pence per C Share by this date).The C Share Offer will close on 5 April 2011 for the 2010/2011 taxyear and on 30 April 2011 for the 2011/2012 tax year (unless extended),allowing investors to subscribe for C Shares in both the 2010/2011 and2011/2012 tax years. The offer price per C Share is £1.00. The C Share Offeris conditional on receiving applications for, in aggregate, a minimum of £1million. If less than £1 million is applied for by the closing date (as may beextended), the Offer will lapse.

Other than as discussed above, the Board is not aware of any significant events or transactions which have occurred in the period from incorporation and the date of this Statement and which have a material impact on the financial position of the Company.

For further information, please contact:

Gary Dale (Investec Structured Products) 020 7597 4065

John Glencross (Calculus Capital Limited) 020 7493 4940

vendor
Date   Source Headline
22nd Apr 20263:39 pmRNSTransaction in Own Shares
31st Mar 20265:55 pmRNSDirectorate change
25th Mar 20262:23 pmRNSIssue of Equity
18th Feb 20263:14 pmRNSIssue of Equity
22nd Jan 20269:29 amRNSTransaction in Own Shares
16th Jan 20264:34 pmRNSNet Asset Value(s)
14th Jan 20263:00 pmRNSDividend Declaration
18th Dec 20252:30 pmRNSIssue of Equity
18th Dec 20252:30 pmRNSIssue of Equity
17th Dec 20253:15 pmRNSIssue of Equity
15th Dec 20253:10 pmRNSHalf-year Financial Report
14th Oct 20254:33 pmRNSTransaction in Own Shares
3rd Oct 202511:42 amRNSPublication of a Prospectus
2nd Oct 20254:29 pmRNSIssue of Equity
24th Sep 202511:22 amRNSResult of AGM & Change in Directorship
2nd Sep 20252:48 pmRNSIssue of Equity
28th Aug 202512:38 pmRNSPublication of Supplementary Prospectus
27th Aug 20252:52 pmRNSNet Asset Value
31st Jul 20259:46 amRNSAnnual Report with updated dividend details
30th Jul 202511:31 amRNSAnnual Financial Report &Related Party Transaction
3rd Jul 20259:17 amRNSIssue of Equity
10th Jun 20254:41 pmRNSTransaction in Own Shares
5th Jun 20254:39 pmRNSTransaction in Own Shares
4th Apr 20255:15 pmRNSIssue of Equity
26th Mar 20253:21 pmRNSIssue of Equity
11th Mar 20255:11 pmRNSChange of auditor
20th Feb 20254:30 pmRNSIssue of Equity
12th Feb 20254:39 pmRNSTransaction in Own Shares
21st Jan 20255:11 pmRNSNet Asset Value(s)
10th Jan 20253:46 pmRNSIssue of Equity update
18th Dec 20244:24 pmRNSIssue of Equity - 18 December 2024
5th Dec 20245:25 pmRNSHalf-year Report
14th Oct 20241:40 pmRNSPublication of a Prospectus
8th Oct 20245:23 pmRNSTransaction in Own Shares
9th Sep 202411:48 amRNSStatement re Intention to Fund Raise
29th Aug 20245:32 pmRNSIssue of Equity
22nd Aug 20244:27 pmRNSResults of Annual General Meeting
31st Jul 20245:44 pmRNSIssue of Equity
17th Jul 20241:51 pmRNSNet Asset Value(s)
11th Jul 20245:38 pmRNSAnnual Financial Report
24th Apr 20244:49 pmRNSTransaction in Own Shares
5th Apr 20242:54 pmRNSIssue of Equity - 5 April 2024
22nd Feb 20244:38 pmRNSDirectorship Change
15th Feb 202411:53 amRNSIssue of Equity - 15 February 2024
1st Feb 20244:38 pmRNSNet Asset Value - 31 December 2023
10th Jan 20245:27 pmRNSTransaction in Own Shares
21st Dec 202310:08 amRNSDirectorate Change
15th Dec 20233:25 pmRNSIssue of Equity - 15 December 2023
20th Nov 20232:11 pmRNSSeptember 2023 NAV Announcement
13th Nov 20234:46 pmRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.